Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Quidel Corporation    QDEL


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Quidel Corporation : Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season

11/19/2020 | 10:13am EST

With the common symptoms of flu, COVID-19 and Lyme disease all converging to form a frightening respiratory season, health care professionals nationwide will converge themselves to join an important webinar on Dec. 3 focused on how to correctly diagnose and treat these look-alike conditions. The webinar is being sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

As reported by the Centers for Disease Control and Prevention, the trio of Lyme disease, flu and COVID-19 share the common symptoms of fever/chills, fatigue, muscle aches and headaches. That makes it both challenging and critical for health care professionals to properly distinguish one from the other so that they can correctly treat their patients for the corresponding ailment.

“In particular, physicians need to have their radar up for Lyme disease, which is known as ‘The Great Imitator’ because its symptoms often mimic those of flu and, most recently, COVID-19 infections,” said Roxanne Carfora, D.O., who will be conducting the webinar. “Early diagnosis of Lyme disease is critical because if not caught early or if misdiagnosed, Lyme disease can have long-term debilitating consequences. With Lyme disease afflicting as many as 400,000 Americans each year, we view this as an epidemic within the pandemic.”

A recovering Lyme disease patient herself, Dr. Carfora is board certified in anti-aging and functional medicine and has been practicing family medicine on Long Island for more than 25 years. She is the founder of New York-based Ageless MD, which combines family medicine, anti-aging medicine and aesthetics in one patient-friendly environment. Dr. Carfora is a graduate of New York College of Osteopathic Medicine, host of the radio program “Getting You Healthy, Naturally” and co-author of “Ageless Adventures,” which provides tips on how to live a more active, healthy lifestyle.

Lyme disease is a bacterial infection that is spread when people are bitten by an infected deer tick. It can strike anyone at any age and can lead to a number of serious, life-threatening problems if not caught early. Leading the way in Lyme disease testing is Quidel’s innovative Sofia® 2 Lyme FIA test. This test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. With appropriate antibiotic treatment, most people with Lyme disease recover completely; but the key is catching it early, and that means not hesitating to get tested.

Among those expected to attend the free Dec. 3 webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers and others interested in the subject. The webinar, titled, “Doctor, I’m exhausted and have a fever. Do I have COVID? Could it be the flu or even Lyme disease?” will take place from noon-1 p.m. (EDT). To register, visit quidel.com/webinars.

About Quidel Corporation

Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com.

© Business Wire 2020
01/13QUIDEL : Presents at JPM Healthcare Conference
01/07QUIDEL CORP /DE/ : Results of Operations and Financial Condition, Regulation FD ..
01/07QUIDEL : Posts Preliminary Q4 Revenue Range Below Street View -- Shares Sink
01/07QUIDEL : Announces Preliminary Revenue for Fourth Quarter 2020; Will Present Vir..
2020QUIDEL : Solana COVID-19 Test Secures FDA Emergency Use Authorization
2020QUIDEL : Receives Emergency Use Authorization for Moderately Complex Solana® SAR..
2020UPDATE : Quidel Gets FDA Emergency Use Authorization for QuickVue Antigen Test f..
2020QUIDEL : Gets FDA Emergency Use Authorization for QuickVue Antigen Test for COVI..
2020QUIDEL : Receives Emergency Use Authorization for QuickVue® SARS Rapid Antigen T..
2020QUIDEL CORPORATION : CEO Douglas Bryant Named Executive of the Year in MedTech D..
More news
Financials (USD)
Sales 2020 1 665 M - -
Net income 2020 770 M - -
Net cash 2020 150 M - -
P/E ratio 2020 11,5x
Yield 2020 -
Capitalization 8 602 M 8 602 M -
EV / Sales 2020 5,08x
EV / Sales 2021 2,01x
Nbr of Employees 1 250
Free-Float 88,2%
Duration : Period :
Quidel Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUIDEL CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 282,00 $
Last Close Price 204,49 $
Spread / Highest target 81,4%
Spread / Average Target 37,9%
Spread / Lowest Target -14,4%
EPS Revisions
Managers and Directors
Douglas C. Bryant President, Chief Executive Officer & Director
Kenneth F. Buechler Chairman
Robert Joseph Bujarski Chief Operating Officer
Randall J. Steward Chief Financial Officer
Werner Kroll Senior Vice President-Research & Development
Sector and Competitors